Aafia Chaudhry M.D. is a founding partner at Noesis LLC, an investment-management firm focused on the pharmaceutical and biotechnology sectors. She originally trained in general surgery prior to transitioning into the health-care industry. Aafia has been an active life-sciences investor for the past nine years and is an expert in pharmaceutical life-cycle management strategy. She was formerly president of 81qd, a strategic data-analytics consultancy, and most recently served as vice president of strategic market planning at WebMD Health Corp.
Recent Articles By The Author
Chelsea Therapeutics: Northera FDA Panel Live Blog
A panel of experts is debating the merits of Chelsea's drug as a treatment for a debilitating form of low blood pressure. Follow along with our live blog.
Unigene Faces Do-or-Die FDA Panel Tuesday
An FDA panel's decision on the safety of calcitonin to treat osteoporosis will have a big impact on Unigene's stock price.
Gauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results
TheStreet contributor Aafia Chaudhry says prior study results raise the risk of a bad outcome in Ziopharm's phase III sarcoma drug trial.
Sarepta Bear Speaks: Eteplirsen Accelerated Approval Will Be Denied
Eteplirsen data are biased and flimsy, and FDA will ask for another clinical trial, says TheStreet contributor Aafia Chaudhry.
Depomed Bear Case: FDA Panel Will Ding Serada
New contributor Aafia Chaudhry explains why she believes Depomed's hot flash drug has no future.